What is Likarda?
Likarda operates as a high-precision biotechnology platform dedicated to the stabilization and controlled release of advanced therapies. By leveraging proprietary hydrogel encapsulation technologies, the company provides critical infrastructure for cell therapies, biologics, and small molecule treatments. Unlike traditional pharmaceutical manufacturers, Likarda functions as a research-driven partner, offering feasibility studies, preclinical support, and logistics solutions to larger biotechnology and pharmaceutical entities. This strategic positioning allows the firm to act as an enabling force in the drug development lifecycle, ensuring that sensitive therapeutic agents are protected and effectively delivered within the human body.
The company's business model is centered on applied biotechnology support, bridging the gap between laboratory innovation and clinical application. Through its focus on cryopreservation and delivery optimization, Likarda addresses the inherent instability of modern medical treatments, thereby increasing the efficacy and safety profiles of its partners' therapeutic pipelines.
How much funding has Likarda raised?
Likarda has raised a total of $4.1M across 2 funding rounds:
Series A
$4M
Debt
$144K
Series A (2017): $4M, investors not publicly disclosed
Debt (2021): $144K led by PPP
Key Investors in Likarda
PPP
Public-Private Partnership
Undisclosed Investor
A strategic backer participating in early-stage capital rounds to facilitate the development of proprietary encapsulation technologies.
What's next for Likarda?
With the recent influx of capital, Likarda is well-positioned to scale its research operations and deepen its collaborative engagements with major pharmaceutical players. The current funding context, characterized by major enterprise-level support, suggests a transition toward broader commercial adoption of its encapsulation technologies. Future strategic initiatives will likely prioritize the expansion of its preclinical support capabilities and the refinement of its logistics framework to accommodate the growing demand for complex biologics. As the biotechnology landscape shifts toward more personalized and sensitive treatment modalities, Likarda's role as a technical enabler becomes increasingly vital, providing the necessary stability and delivery precision required for next-generation medical breakthroughs.
See full Likarda company page
